BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10950062)

  • 1. Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective?
    Soni A; Sampliner RE; Sonnenberg A
    Am J Gastroenterol; 2000 Aug; 95(8):2086-93. PubMed ID: 10950062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A guide for surveillance of patients with Barrett's esophagus.
    Provenzale D; Kemp JA; Arora S; Wong JB
    Am J Gastroenterol; 1994 May; 89(5):670-80. PubMed ID: 8172136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett's esophagus.
    Gerson L; Lin OS
    Clin Gastroenterol Hepatol; 2007 Mar; 5(3):319-25. PubMed ID: 17368231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy.
    Rubenstein JH; Inadomi JM; Brill JV; Eisen GM
    Clin Gastroenterol Hepatol; 2007 Mar; 5(3):312-8. PubMed ID: 17368230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis.
    Gupta N; Bansal A; Wani SB; Gaddam S; Rastogi A; Sharma P
    Gastrointest Endosc; 2011 Sep; 74(3):610-624.e2. PubMed ID: 21741639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endoscopic versus surgical therapy for early cancer in Barrett's esophagus: a decision analysis.
    Pohl H; Sonnenberg A; Strobel S; Eckardt A; Rösch T
    Gastrointest Endosc; 2009 Oct; 70(4):623-31. PubMed ID: 19394011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
    Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma.
    Avidan B; Sonnenberg A; Schnell TG; Chejfec G; Metz A; Sontag SJ
    Am J Gastroenterol; 2002 Aug; 97(8):1930-6. PubMed ID: 12190156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The influence of Barrett's esophagus on the clinical signs and postoperative results of GERD].
    Endzinas Z; Mickevicius A; Kiudelis M
    Zentralbl Chir; 2004 Apr; 129(2):99-103. PubMed ID: 15106039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recommended endoscopic surveillance of patients with Barrett's esophagus (BE) is a cost-effective strategy?].
    Remes-Troche JM; Ramírez-Arias JF; Gómez-Escudero O; Valdovinos-Andraca F; Vargas-Vorácková F
    Rev Gastroenterol Mex; 2006; 71(1):46-54. PubMed ID: 17061478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of upper GI endoscopy referral volume on the diagnosis of gastroesophageal reflux disease and its complications: a 1-year cross-sectional study in a referral area with 260,000 inhabitants.
    Mäntynen T; Färkkilä M; Kunnamo I; Mecklin JP; Juhola M; Voutilainen M
    Am J Gastroenterol; 2002 Oct; 97(10):2524-9. PubMed ID: 12385433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of endoscopic screening followed by surveillance for Barrett's esophagus: a review.
    Barbiere JM; Lyratzopoulos G
    Gastroenterology; 2009 Dec; 137(6):1869-76. PubMed ID: 19840798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blinded comparison of esophageal capsule endoscopy versus conventional endoscopy for a diagnosis of Barrett's esophagus in patients with chronic gastroesophageal reflux.
    Lin OS; Schembre DB; Mergener K; Spaulding W; Lomah N; Ayub K; Brandabur JJ; Bredfeldt J; Drennan F; Gluck M; Jiranek GC; McCormick SE; Patterson D; Kozarek RA
    Gastrointest Endosc; 2007 Apr; 65(4):577-83. PubMed ID: 17324414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Barrett's esophagus with high-grade dysplasia.
    McAllaster JD; Buckles D; Al-Kasspooles M
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):303-16. PubMed ID: 19275509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness model of endoscopic biopsy for eosinophilic esophagitis in patients with refractory GERD.
    Miller SM; Goldstein JL; Gerson LB
    Am J Gastroenterol; 2011 Aug; 106(8):1439-45. PubMed ID: 21448144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus.
    Das A; Wells C; Kim HJ; Fleischer DE; Crowell MD; Sharma VK
    Endoscopy; 2009 May; 41(5):400-8. PubMed ID: 19418393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endoscopic surveillance in Barrett's esophagus.
    Lunedei V; Bazzoli F; Pozzato P; De Luca L; Zagari RM; Fossi S; Ricciardiello L; Maltoni S; Roda E
    Minerva Gastroenterol Dietol; 2002 Jun; 48(2):63-71. PubMed ID: 16489297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endoscopic screening for gastric cancer.
    Dan YY; So JB; Yeoh KG
    Clin Gastroenterol Hepatol; 2006 Jun; 4(6):709-16. PubMed ID: 16765306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia.
    Anandasabapathy S; Jhamb J; Davila M; Wei C; Morris J; Bresalier R
    Cancer; 2007 Feb; 109(4):668-74. PubMed ID: 17211862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gastroesophageal reflux disease and malignancy].
    Richert Z; Robaszkiewicz M
    Rev Prat; 2008 Sep; 58(13):1414-5, 1417, 1419-20. PubMed ID: 18924321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.